RESUMEN
Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders. Calorie restriction, semaglutide, rosiglitazone, and mitochondrial uncouplers have all demonstrated efficacy against one or more obesity-related metabolic disorders, but it currently remains unclear which therapeutic strategy best targets the combination of hyperglycaemia, liver fat, hypertriglyceridemia, and adiposity. Herein we performed a head-to-head comparison of 5 treatment interventions in the female db/db mouse model of severe metabolic disease. Treatments included â¼60 % calorie restriction (CR), semaglutide, rosiglitazone, BAM15, and niclosamide ethanolamine (NEN). Results showed that BAM15 and CR improved body weight and liver steatosis to levels superior to semaglutide, NEN, and rosiglitazone, while BAM15, semaglutide, and rosiglitazone improved glucose tolerance better than CR and NEN. BAM15, CR, semaglutide, and rosiglitazone all had efficacy against hypertriglyceridaemia. These data provide a comprehensive head-to-head comparison of several key treatment strategies for metabolic disease and highlight the efficacy of mitochondrial uncoupling to correct multiple facets of the metabolic disease milieu in female db/db mice.
Asunto(s)
Diabetes Mellitus Tipo 2 , Enfermedad del Hígado Graso no Alcohólico , Ratones , Animales , Femenino , Niclosamida/uso terapéutico , Rosiglitazona/farmacología , Rosiglitazona/uso terapéutico , Etanolamina/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Restricción Calórica , Etanolaminas/uso terapéutico , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Obesidad/tratamiento farmacológico , Obesidad/metabolismoRESUMEN
Unhealthy dietary habits have been identified as a risk factor for the development and progression of cancer. Therefore, adopting a healthy eating pattern is currently recommended to prevent the onset of different types of cancers, including breast carcinoma. In particular, the Mediterranean diet, based on high consumption of omega-3 polyunsaturated fatty acids (N-3 PUFAs), such as those found in cold-water fish and other seafood, nuts, and seeds, is recommended to reduce the incidence of several chronic-degenerative diseases. Indeed, the consumption of N-3 PUFAs, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), reduced the risk of different types of cancer, including breast cancer. Moreover, they can counteract breast cancer progression and reduce the side effects of chemotherapy in breast cancer survival. Studies have demonstrated that DHA, exhibiting greater antitumor activity than EPA in breast cancer, can be attributed to its direct impact on breast cancer cells and also due to its conversion into various metabolites. N-docosahexaenoyl ethanolamine, DHEA, is the most studied DHA derivative for its therapeutic potential in breast cancer. In this review, we emphasize the significance of dietary habits and the consumption of N-3 polyunsaturated fatty acids, particularly DHA, and we describe the current knowledge on the antitumoral action of DHA and its derivative DHEA in the treatment of breast cancer.
Asunto(s)
Ácidos Grasos Omega-3 , Neoplasias , Animales , Etanolamina/uso terapéutico , Ácidos Docosahexaenoicos/farmacología , Ácidos Docosahexaenoicos/uso terapéutico , Ácido Eicosapentaenoico/farmacología , Deshidroepiandrosterona , Neoplasias/tratamiento farmacológicoRESUMEN
While the goal of most anticancer treatments is to kill cancer cells, some therapies halt cancer progression by inducing cancer cell differentiation. For example, retinoic acid induces neuroblastoma cell differentiation in vitro and is used as maintenance therapy for children with high-risk neuroblastoma. A new study by Jiang and colleagues has revealed the mitochondrial uncoupler niclosamide ethanolamine (NEN) induces neuroblastoma cell differentiation in vitro and slows neuroblastoma tumor growth in vivo. Mitochondrial uncoupler molecules alter cell metabolism by forcing cells to "burn" more nutrients, resulting in a switch from anabolic to catabolic metabolism. NEN-induced neuroblastoma cell differentiation was associated with disruption of Warburg metabolism, epigenetic remodeling, and downregulation of key oncogenic drivers of neuroblastoma development, including MYCN. NEN is currently used as an antiparasitic worm treatment and is safe to use in children but has poor pharmacokinetic properties. However, derivatives of NEN and structurally distinct uncouplers that have improved pharmacokinetic properties are in development. Results of this study ignite the idea that mitochondrial uncouplers could be used as differentiating agents and expand the pharmacotherapy toolkit to treat cancer, including neuroblastoma. See related article by Jiang et al., p. 181.
Asunto(s)
Antineoplásicos , Neuroblastoma , Humanos , Epigenoma/efectos de los fármacos , Antineoplásicos/farmacología , Tretinoina/farmacología , Diferenciación Celular/efectos de los fármacos , Niclosamida/farmacología , Etanolamina/farmacología , Etanolamina/uso terapéutico , Neuroblastoma/patologíaRESUMEN
The Warburg effect is the major metabolic hallmark of cancer. According to Warburg himself, the consequence of the Warburg effect is cell dedifferentiation. Therefore, reversing the Warburg effect might be an approach to restore cell differentiation in cancer. In this study, we used a mitochondrial uncoupler, niclosamide ethanolamine (NEN), to activate mitochondrial respiration, which induced neural differentiation in neuroblastoma cells. NEN treatment increased the NAD+/NADH and pyruvate/lactate ratios and also the α-ketoglutarate/2-hydroxyglutarate (2-HG) ratio. Consequently, NEN treatment induced promoter CpG island demethylation and epigenetic landscape remodeling, activating the neural differentiation program. In addition, NEN treatment upregulated p53 but downregulated N-Myc and ß-catenin signaling in neuroblastoma cells. Importantly, even under hypoxia, NEN treatment remained effective in inhibiting 2-HG generation, promoting DNA demethylation, and suppressing hypoxia-inducible factor signaling. Dietary NEN intervention reduced tumor growth rate, 2-HG levels, and expression of N-Myc and ß-catenin in tumors in an orthotopic neuroblastoma mouse model. Integrative analysis indicated that NEN treatment upregulated favorable prognosis genes and downregulated unfavorable prognosis genes, which were defined using multiple neuroblastoma patient datasets. Altogether, these results suggest that mitochondrial uncoupling is an effective metabolic and epigenetic therapy for reversing the Warburg effect and inducing differentiation in neuroblastoma. SIGNIFICANCE: Targeting cancer metabolism using the mitochondrial uncoupler niclosamide ethanolamine leads to methylome reprogramming and differentiation in neuroblastoma, providing a therapeutic opportunity to reverse the Warburg effect and suppress tumor growth. See related commentary by Byrne and Bell, p.167.
Asunto(s)
Diferenciación Celular , Epigenoma , Neuroblastoma , Efecto Warburg en Oncología , Animales , Ratones , beta Catenina/genética , Diferenciación Celular/genética , Línea Celular Tumoral , Epigenoma/genética , Epigenoma/fisiología , Etanolamina/farmacología , Etanolamina/uso terapéutico , Etanolaminas/uso terapéutico , Hipoxia/tratamiento farmacológico , Neuroblastoma/genética , Neuroblastoma/patología , Niclosamida/farmacología , Efecto Warburg en Oncología/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/fisiologíaRESUMEN
Rationale: Cancer cells rely on glucose metabolism for fulfilling their high energy demands. We previously reported that monoethanolamine (Etn), an orally deliverable lipid formulation, reduced intracellular glucose and glutamine levels in prostate cancer (PCa). Glucose deprivation upon Etn treatment exacerbated metabolic stress in PCa, thereby enhancing cell death. Moreover, Etn was potent in inhibiting tumor growth in a PCa xenograft model. However, the precise mechanisms underlying Etn-induced metabolic stress in PCa remain elusive. The purpose of the present study was to elucidate the mechanisms contributing to Etn-mediated metabolic rewiring in PCa. Methods: Glucose transporters (GLUTs) facilitate glucose transport across the plasma membrane. Thus, we assessed the expression of GLUTs and the internalization of GLUT1 in PCa. We also evaluated the effects of Etn on membrane dynamics, mitochondrial structure and function, lipid droplet density, autophagy, and apoptosis in PCa cells. Results: Compared to other GLUTs, GLUT1 was highly upregulated in PCa. We observed enhanced GLUT1 internalization, altered membrane dynamics, and perturbed mitochondrial structure and function upon Etn treatment. Etn-induced bioenergetic stress enhanced lipolysis, decreased lipid droplet density, promoted accumulation of autophagosomes, and increased apoptosis. Conclusion: We provide the first evidence that Etn alters GLUT1 trafficking leading to metabolic stress in PCa. By upregulating phosphatidylethanolamine (PE), Etn modulates membrane fluidity and affects mitochondrial structure and function. Etn also induces autophagy in PCa cells, thereby promoting apoptosis. These data strongly suggest that Etn rewires cellular bioenergetics and could serve as a promising anticancer agent for PCa.
Asunto(s)
Etanolamina/farmacología , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/metabolismo , Adulto , Animales , Apoptosis/efectos de los fármacos , Autofagosomas/metabolismo , Autofagia/efectos de los fármacos , Línea Celular Tumoral , Etanolamina/metabolismo , Etanolamina/uso terapéutico , Glucosa/deficiencia , Glucosa/metabolismo , Proteínas Facilitadoras del Transporte de la Glucosa/efectos de los fármacos , Proteínas Facilitadoras del Transporte de la Glucosa/metabolismo , Transportador de Glucosa de Tipo 1/efectos de los fármacos , Transportador de Glucosa de Tipo 1/metabolismo , Humanos , Masculino , Ratones , Ratones Desnudos , Persona de Mediana Edad , Mitocondrias/metabolismo , Próstata/patología , Neoplasias de la Próstata/fisiopatología , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
BACKGROUND: N-docosahexaenoyl ethanolamine (DHEA; also known as synaptamide) binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties in vitro. However, the in vivo effects of DHEA remain unknown. Therefore, this study was designed to understand the effects of DHEA in models of pain and inflammation in mice. METHODS: The intraplantar formaldehyde assay, hot water tail withdrawal assay and hotplate model were used to assess the antinociceptive properties of DHEA in mice. The mechanism of action was studied by antagonising the cannabinoid receptors, transient receptor potential vanilloid 1 (TRPV1) ion channel, peroxisome proliferator-activated receptors (PPARs) and G-protein receptor 55 (GPR55). RESULTS: N-docosahexaenoyl ethanolamine (2-10 mg/kg) reduced the levels of nociceptive and inflammatory pain-related behaviour over 60 min in the intraplantar formaldehyde assay via both intraperitoneal and local intraplantar administration. The area under the curve analysis showed the overall antinociceptive effects of DHEA (10 mg/kg) were not modulated by pre-treatment with antagonists for the cannabinoid receptors, TRPV1ion channel, PPARα, PPARγ or GPR55. However, the time-course analysis showed that within the early inflammatory phase, antagonism of the CB2 receptor, PPARα and PPARγ led to a partial reversal of the antinociceptive effects of DHEA. In the hot water tail withdrawal and hotplate models of thermal nociception, DHEA (2-10 mg/kg) did not have any antinociceptive effects. CONCLUSIONS: N-docosahexaenoyl ethanolamine reduced the level of formaldehyde-induced nociceptive and inflammatory pain-related behaviour; however, was not active in thermal nociceptive models. This study highlights the potential of DHEA for the treatment of acute inflammatory pain. SIGNIFICANCE: This study shows that both intraperitoneal and intraplantar administration of DHEA reduces the level of formaldehyde-induced nociceptive and inflammatory pain.
Asunto(s)
Etanolamina , Etanolaminas , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Etanolamina/uso terapéutico , Etanolaminas/uso terapéutico , Masculino , Ratones , Dolor/tratamiento farmacológico , Receptor Cannabinoide CB1 , Receptor Cannabinoide CB2 , Receptores de Cannabinoides/uso terapéuticoRESUMEN
Background: Although sclerotherapy is a common treatment for benign oral vascular lesions, there is no well standardized protocol for this purpose. The aim of the present study was to describe the clinical characteristics of patients treated by sclerotherapy with ethanolamine oleate (EO), in order to contribute to a better understanding of this technique. Material and Methods: Medical records and images of 90 patients treated by the same sclerotherapy protocol were retrieved and analysed. Thus, 43 cases with complete information were selected and described. Results: The most affected age group was 41-70 years, with a female predominance and 86% of patients being Caucasian. Lips were the most affect site (70%) followed by the tongue (16%). Regarding clinical appearance, approximately 90% of lesions were classified as nodules, and 90% of patients reported no pain. Approximately 40% of lesions were 0.5-1.0 cm in size. In 58% of the patients, only one application of ethanolamine oleate was necessary. The application doses varied according to the lesion size and number of applications. Complete clinical regression occurred in 91% of cases, whereas 9% showed partial regression. Conclusions: Sclerotherapy with EO is an acceptable, effective and affordable treatment for benign oral vascular lesions (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Lesiones del Sistema Vascular/diagnóstico , Lesiones del Sistema Vascular/terapia , Escleroterapia/métodos , Etanolamina/uso terapéutico , Malformaciones Vasculares/terapia , Enfermedades de la Boca/terapia , Estudios Retrospectivos , Hemangioma/complicaciones , Hemangioma/terapia , Malformaciones Vasculares/complicaciones , Várices/complicacionesRESUMEN
Metabolism of cancer cells is characterized by aerobic glycolysis, or the Warburg effect. Aerobic glycolysis reduces pyruvate flux into mitochondria, preventing a complete oxidation of glucose and shunting glucose to anabolic pathways essential for cell proliferation. Here we tested a new strategy, mitochondrial uncoupling, for its potential of antagonizing the anabolic effect of aerobic glycolysis and for its potential anticancer activities. Mitochondrial uncoupling is a process that facilitates proton influx across the mitochondrial inner membrane without generating ATP, stimulating a futile cycle of acetyl- CoA oxidation. We tested two safe mitochondrial uncouplers, NEN (niclosamide ethanolamine) and oxyclozanide, on their metabolic effects and anti-cancer activities. We used metabolomic NMR to examine the effect of mitochondrial uncoupling on glucose metabolism in colon cancer MC38 cells. We further tested the anti-cancer effect of NEN and oxyclozanide in cultured cell models, APCmin/+ mouse model, and a metastatic colon cancer mouse model. Using a metabolomic NMR approach, we demonstrated that mitochondrial uncoupling promotes pyruvate influx to mitochondria and reduces various anabolic pathway activities. Moreover, mitochondrial uncoupling inhibits cell proliferation and reduces clonogenicity of cultured colon cancer cells. Furthermore, oral treatment with mitochondrial uncouplers reduces intestinal polyp formation in APCmin/+ mice, and diminishes hepatic metastasis of colon cancer cells transplanted intrasplenically. Our data highlight a unique approach for targeting cancer cell metabolism for cancer prevention and treatment, identified two prototype compounds, and shed light on the anti-cancer mechanism of niclosamide.
Asunto(s)
Antinematodos/uso terapéutico , Neoplasias del Colon/complicaciones , Etanolamina/uso terapéutico , Neoplasias Hepáticas/secundario , Niclosamida/uso terapéutico , Oxiclozanida/uso terapéutico , Animales , Antinematodos/farmacología , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/patología , Etanolamina/farmacología , Humanos , Neoplasias Hepáticas/patología , Ratones , Niclosamida/farmacología , Oxiclozanida/farmacologíaRESUMEN
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates a multitude of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation. Because of the ability of S1P1 receptor agonists to suppress lymphocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases. In this article, the discovery of selective, direct acting S1P1 agonists utilizing an ethanolamine scaffold containing a terminal carboxylic acid is described. Potent S1P1 agonists such as compounds 18a and 19a which have greater than 1000-fold selectivity over S1P3 are described. These compounds efficiently reduce blood lymphocyte counts in rats through 24 h after single doses of 1 and 0.3 mpk, respectively. Pharmacodynamic properties of both compounds are discussed. Compound 19a was further studied in two preclinical models of disease, exhibiting good efficacy in both the rat adjuvant arthritis model (AA) and the mouse experimental autoimmune encephalomyelitis model (EAE).
Asunto(s)
Etanolamina/química , Etanolamina/farmacología , Linfocitos/efectos de los fármacos , Receptores de Lisoesfingolípidos/agonistas , Animales , Artritis/tratamiento farmacológico , Perros , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Etanolamina/farmacocinética , Etanolamina/uso terapéutico , Femenino , Haplorrinos , Humanos , Recuento de Linfocitos , Linfocitos/citología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratas , Ratas Endogámicas Lew , Receptores de Lisoesfingolípidos/metabolismo , Relación Estructura-ActividadRESUMEN
N-3 Long-chain polyunsaturated fatty acids (n-3 LC-PUFAs), in particular α-linolenic acid (18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) are receiving much attention because of their presumed beneficial health effects. To explain these, a variety of mechanisms have been proposed, but their interactions with the endocannabinoid system have received relatively little attention so far. However, it has already been shown some time ago that consumption of n-3 LC-PUFAs not only affects the synthesis of prototypic endocannabinoids like anandamide but also stimulates the formation of specific n-3 LC-PUFA-derived conjugates with ethanolamine, dopamine, serotonin or other amines. Some of these fatty amides show overlapping biological activities with those of typical endocannabinoids, whereas others possess distinct and sometimes largely unknown receptor affinities and other properties. The ethanolamine and dopamine conjugates of DHA have been the most investigated thus far. These mediators may provide promising new leads to the field of inflammatory and neurological disorders and for other pharmacological applications, including their use as carrier molecules for neurotransmitters to target the brain. Furthermore, combinations of n-3 LC-PUFA-derived fatty acid amides, their precursors and FAAH inhibitors offer possibilities to optimise their effects in health and disease.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Agonistas de Receptores de Cannabinoides/uso terapéutico , Suplementos Dietéticos , Endocannabinoides/uso terapéutico , Ácidos Grasos Omega-3/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Alcamidas Poliinsaturadas/uso terapéutico , Acilación , Animales , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/metabolismo , Agonistas de Receptores de Cannabinoides/química , Agonistas de Receptores de Cannabinoides/metabolismo , Ácidos Docosahexaenoicos/análogos & derivados , Ácidos Docosahexaenoicos/metabolismo , Ácidos Docosahexaenoicos/uso terapéutico , Dopamina/análogos & derivados , Dopamina/metabolismo , Dopamina/uso terapéutico , Sistemas de Liberación de Medicamentos , Ácido Eicosapentaenoico/análogos & derivados , Ácido Eicosapentaenoico/metabolismo , Ácido Eicosapentaenoico/uso terapéutico , Endocannabinoides/química , Endocannabinoides/metabolismo , Etanolamina/química , Etanolamina/metabolismo , Etanolamina/uso terapéutico , Ácidos Grasos Omega-3/química , Ácidos Grasos Omega-3/metabolismo , Aceites de Pescado/química , Peces , Humanos , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/metabolismo , Alcamidas Poliinsaturadas/química , Alcamidas Poliinsaturadas/metabolismo , Receptores de Cannabinoides/química , Receptores de Cannabinoides/metabolismo , Alimentos Marinos/análisis , Ácido alfa-Linolénico/análogos & derivados , Ácido alfa-Linolénico/metabolismo , Ácido alfa-Linolénico/uso terapéuticoRESUMEN
In addition to their antihistamine effects, H1-receptor antagonists possess pharmacological properties that are not uniformly distributed among this class of drugs, such as anti-inflammatory, anti-allergic and antiplatelet activities. In this paper, Cyclizine (1-benzhydryl-4-methyl-piperazine, I), bromodiphenhydramine (2-[(4-bromophenyl)-phenylmethoxy]-N, N-dimethylethanamine, II) and some of their new piperazine and ethanolamine derivatives (III-VIII) inducing changes in substitution of phenyl and amine moieties were synthesized and their acute and chronic antiinflammatory effects were evaluated by standard pharmacological tests. The results showed that substitution of phenyl by tolyl, anisol and cumene groups in piperazine family could remarkably decrease acute inflammation in these new drugs. Also, substitution of dimethylamine by morpholine group could not decrease this inflammation in new synthesized ethanolamine family. But the results from the cotton pellet-induced granuloma formation in rats showed that none of drugs (I-VIII) were effective to reduce the chronic inflammation.
Asunto(s)
Antiinflamatorios/química , Etanolamina/química , Antagonistas de los Receptores Histamínicos H1/química , Piperazinas/química , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/uso terapéutico , Fibra de Algodón , Difenhidramina/análogos & derivados , Difenhidramina/síntesis química , Difenhidramina/química , Difenhidramina/uso terapéutico , Edema/inducido químicamente , Edema/tratamiento farmacológico , Etanolamina/síntesis química , Etanolamina/uso terapéutico , Granuloma/inducido químicamente , Granuloma/tratamiento farmacológico , Antagonistas de los Receptores Histamínicos H1/síntesis química , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Masculino , Piperazina , Piperazinas/síntesis química , Piperazinas/uso terapéutico , Ratas , Ratas Wistar , Receptores Histamínicos H1/química , Receptores Histamínicos H1/metabolismoRESUMEN
Vascular malformations or even hemangiomas need therapeutic intervention if they start to cause clinical symptoms or personal discomfort. Different therapeutic modalities, including cryotherapy, corticosteroids, laser therapy, sclerotherapy, surgery, and/or embolization, can be performed successfully. Sclerotherapy with monoethanolamine is a relatively simple and effective method to treat low flow vascular lesions. We presented a report of six cases of vascular malformations treated with monoethanolamine. There were 3 male and 3 female patients, with an age range of 20 to 68 years. The patients were submitted to applications according to clinical response and/or tolerability. In all cases, low-flow vascular lesions were recorded and submitted to infiltration with 2.5% monoethanolamine, directly into the lesions. The volume applied was approximately the middle of affected area. Vascular lesions were characterized as low-flow due to absence of arterial pulsation and flat consistence. The sclerosis with 2.5% monoethanolamine resulted in complete or partial involution, without severe complications.
Asunto(s)
Etanolamina/uso terapéutico , Boca/irrigación sanguínea , Escleroterapia , Malformaciones Vasculares/terapia , Adulto , Anciano , Velocidad del Flujo Sanguíneo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Malformaciones Vasculares/fisiopatologíaAsunto(s)
Moduladores de Receptores de Cannabinoides/uso terapéutico , Emolientes/uso terapéutico , Endocannabinoides , Prurito/terapia , Uremia/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Amidas , Etanolamina/uso terapéutico , Etanolaminas , Femenino , Estudios de Seguimiento , Gelatina , Humanos , Masculino , Persona de Mediana Edad , Ácidos Palmíticos/uso terapéutico , Prurito/etiología , Diálisis Renal , Cuidados de la PielRESUMEN
An inhaled corticosteroid (ICS) and a long acting beta agonist (LABA) are combined in an inhaler for treatment of persistent asthma. There is evidence that maintenance therapy with a combination ICS/LABA inhaler improves clinical outcomes and reduces airflow obstruction in patients with persistent asthma, who are not well controlled even when using ICS maintenance therapy. There is evidence that a combination ICS/LABA inhaler may also play a role in initial maintenance therapy for patients with mild persistent asthma, who have never used ICS therapy. There is no evidence regarding the use of combination therapy in intermittent asthma. Oral candidal infections, hoarseness and pharyngolaryngeal pain are the most frequently reported adverse events. Combination inhaler therapy can improve compliance with guidelines that recommend a LABA only be used with concurrent ICS administration.
Asunto(s)
Corticoesteroides/uso terapéutico , Agonistas Adrenérgicos beta/uso terapéutico , Albuterol/uso terapéutico , Androstadienos/uso terapéutico , Asma/tratamiento farmacológico , Budesonida/uso terapéutico , Etanolamina/uso terapéutico , Administración por Inhalación , Corticoesteroides/administración & dosificación , Corticoesteroides/efectos adversos , Corticoesteroides/economía , Agonistas Adrenérgicos beta/administración & dosificación , Agonistas Adrenérgicos beta/efectos adversos , Agonistas Adrenérgicos beta/economía , Adulto , Albuterol/administración & dosificación , Albuterol/efectos adversos , Albuterol/análogos & derivados , Albuterol/economía , Androstadienos/administración & dosificación , Androstadienos/efectos adversos , Androstadienos/economía , Budesonida/administración & dosificación , Budesonida/efectos adversos , Budesonida/economía , Canadá , Aprobación de Drogas , Costos de los Medicamentos , Quimioterapia Combinada , Etanolamina/administración & dosificación , Etanolamina/efectos adversos , Etanolamina/economía , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Glucocorticoides/economía , Glucocorticoides/uso terapéutico , Humanos , Cooperación del Paciente , Guías de Práctica Clínica como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Reino Unido , Estados UnidosRESUMEN
O hemangioma é uma lesão vascular que, apesar de sua natureza benigna, requer tratamento, especialmente em regiões que possam vir a ser traumatizada ou que impliquem em perda funcional e/ou estética. Este trabalho objetiva apresentar uma revisão de literatura e caso clínico desta patologia, retratando seus aspectos clínicos, histológicos, seu diagnóstico, com estoque no tratamento, abordando principalmente a terapêutica adotada no paciente,a qual utilizou o oleato de etanolamina a 5 por cento, como agente esclerosante.
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Ácido Oléico/uso terapéutico , Etanolamina/uso terapéutico , Hemangioma/terapia , EscleroterapiaRESUMEN
BACKGROUND: The aim of this study was to retrospectively evaluate the short-and long-term effectiveness of different methods of endoscopic treatment for bleeding Dieulafoy's lesions. METHODS: Patients were allocated into 2 groups according to the hemostatic method applied: (1) injection group (epinephrine and/or ethanolamine oleate), and (2) thermal coagulation group (heat probe), either alone or combined with epinephrine injection. The combination of epinephrine and ethanolamine oleate was used in 5 patients, epinephrine alone in 3, ethanolamine oleate alone in one, heat probe and epinephrine in 8, and heat probe alone in 1 patient. RESULTS: Dieulafoy's lesions were found in 18 (1%) of 1750 patients with acute nonvariceal upper GI bleeding. Comorbid conditions were present in 5 (28%) patients. Initial hemostasis was achieved endoscopically in 13 patients (72%) and permanent hemostasis in 17 patients (94%). Bleeding recurred in 5 patients (2 with concomitant disease) in the injection group; 3 were successfully retreated by heat probe coagulation and epinephrine injection, 1 with hemoclip application and 1 by surgery. There was no recurrent bleeding in thermal treatment group. Thermal treatment was significantly superior to injection (p = 0.0029). CONCLUSIONS: Endoscopic thermal coagulation with or without epinephrine injection should be the initial treatment of choice for Dieulafoy's lesions. Mortality is lowest in patients with no significant comorbidity and an unremarkable medical history.
Asunto(s)
Electrocoagulación , Epinefrina/uso terapéutico , Etanolamina/uso terapéutico , Hemorragia Gastrointestinal/terapia , Hemostasis Endoscópica/métodos , Soluciones Esclerosantes/uso terapéutico , Vasoconstrictores/uso terapéutico , Adulto , Anciano , Epinefrina/administración & dosificación , Etanolamina/administración & dosificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Soluciones Esclerosantes/administración & dosificación , Resultado del Tratamiento , Vasoconstrictores/administración & dosificaciónRESUMEN
BACKGROUND: To evaluate the safety and efficiency of variceal ligation compared with endoscopic sclerotherapy, 88 patients with cirrhosis with recent variceal bleeding were randomized to undergo either treatment. METHODS: Sclerotherapy was performed using ethanolamine and polidocanol injection at 1, 2, and 3 weeks and every 3 weeks thereafter. The Stiegmann-Goff device was used for variceal ligation at the same intervals. RESULTS: The rate of variceal eradication was the same for both groups, but eradication was accomplished sooner in patients undergoing variceal ligation (5.3+/-1.6 vs. 6.6+/-2.4 endoscopic sessions, p < 0.05) and with fewer complications (19 vs. 6, p < 0.005). The rate of recurrent bleeding was lower in patients treated by ligation (31% vs. 50%, p < 0.05). After eradication, variceal recurrence was more frequent in patients treated by variceal ligation at 1 and 3 years (47% and 92% vs. 23% and 55%, p < 0.01). Portal hypertensive gastropathy was significantly worse in the patients who had variceal ligation (17 patients vs. 6, p < 0.01). Survival and treatment failure were similar in both groups. CONCLUSIONS: Variceal ligation was superior to sclerotherapy in terms of the rate of recurrent bleeding and the occurrence of complications but worse with respect to recurrence of varices and the evolution of portal hypertensive gastropathy. Long-term follow-up studies are required to find out whether there are deleterious effects of variceal ligation.
Asunto(s)
Várices Esofágicas y Gástricas/terapia , Hemorragia Gastrointestinal/terapia , Hemostasis Endoscópica , Várices Esofágicas y Gástricas/complicaciones , Várices Esofágicas y Gástricas/epidemiología , Etanolamina/uso terapéutico , Femenino , Hemorragia Gastrointestinal/epidemiología , Hemorragia Gastrointestinal/etiología , Humanos , Ligadura , Masculino , Persona de Mediana Edad , Polidocanol , Polietilenglicoles/uso terapéutico , Estudios Prospectivos , Recurrencia , Soluciones Esclerosantes/uso terapéutico , Escleroterapia , Resultado del TratamientoRESUMEN
BACKGROUND AND STUDY AIMS: Endoscopic sclerotherapy has been a very useful method for the management of bleeding vascular lesions of the gastrointestinal tract. In this report, the injection of a sclerosant agent was evaluated for the treatment of angiodysplasias of the colon. PATIENTS AND METHODS: In a prospective study in eight patients an ethanolamine solution was injected under endoscopic observation directly into 15 lesions, typically angiodysplasias of the right colon at the index colonoscopy, and into another eight de novo lesions found at subsequent examinations. The needle injector was intended to be placed very carefully into the lesion, tangentially to the mucosal surface, to avoid penetrating the bowel wall. RESULTS: Clinical follow-up showed that in six out of the eight patients (75%) no further evidence of lower intestinal hemorrhage was registered after the sclerotherapy; follow-up ranged from 22 to 36 months. Of the four patients who needed blood transfusion before the treatment because of intestinal bleeding, only one required blood transfusion after the sclerotherapy. Neither immediate nor late complications were recorded; often light bleeding occurred immediately after the injections and stopped spontaneously, except in one case which necessitated additional injection of the sclerosant. On the other hand, only one patient had light transient right lower quadrant pain after the injection, which subsided without any medication. CONCLUSIONS: Our method was shown to be feasible and safe. The success of the intralesional injection of the sclerosing agent may be predicted when changes in the mucosal surface are observed: (a) immediately after the injection sufficient sclerosant is deemed to have been injected and to the proper depth in the bowel wall, if the mucosa bulges while the solution is being injected; and (b) if a shallow ulceration is seen in an early subsequent reexamination where the treated lesion was located, allowing scar tissue produced by the healing process of the ulcer to replace the former vascular lesion.
Asunto(s)
Angiodisplasia/terapia , Enfermedades del Colon/terapia , Etanolamina/uso terapéutico , Hemorragia Gastrointestinal/terapia , Hemostasis Endoscópica , Soluciones Esclerosantes/uso terapéutico , Escleroterapia , Anciano , Angiodisplasia/complicaciones , Colon/irrigación sanguínea , Enfermedades del Colon/complicaciones , Colonoscopía , Estudios de Factibilidad , Femenino , Hemorragia Gastrointestinal/etiología , Humanos , Masculino , Persona de Mediana Edad , Estudios ProspectivosRESUMEN
The effects of ethanolamine on injured liver were investigated by oral administration of ethanolamine to male ddY mice 24 h after carbon tetrachloride (CCl4) injection. The serum aminotransferase activities in mice with liver injury were reduced by ethanolamine treatment (10-30 mg/kg body weight). Drastically increased regenerative reaction of ethanolamine treated-CCl4 injured liver was also observed through an increase in 5-bromo-2'-deoxyuridine uptake. ATP concentration in liver tissue was recovered by administration of ethanolamine. These results suggest that oral administration of ethanolamine accelerates recovery from CCl4-induced liver injury.